Eye Health Advancements and Ongoing Challenges in Africa

By Crystal Lubbe

October 15, 2024

The article titled “Promising progress on eye health in the African region, but challenges remain” from the World Health Organization (WHO) Regional Office for Africa highlights several key points regarding the current state of eye health in the African region. While there has been notable progress in eye health, significant challenges remain that hinder further advancements.

Progress Made

Despite significant challenges, progress has been made in integrating eye health into primary health care services in African countries. The WHO has recorded a decrease in vision loss due to Vitamin A deficiency, onchocerciasis, and trachoma. These gains are critical for improving overall well-being and reducing the economic burden associated with preventable vision loss.

Challenges

A dire shortage of financial resources and the concentration of scarce human resources in urban areas continue to hinder eye health progress. This results in low community awareness and inadequate access to eye care services. Only 14% of people who need cataract surgery receive it, while more than 80% of those with shortsightedness do not receive treatment. This is in stark contrast to other regions like North America, Australasia, Western Europe, and the Asia-Pacific, where the figures are lower than 10%. The global estimated costs of uncorrected refractive errors and cataracts are significant, amounting to US$14.3 billion annually.

Emerging Challenges

There is a rising trend of eye health challenges related to aging populations, unhealthy lifestyles, and noncommunicable diseases such as diabetic retinopathy and age-related macular degeneration.

WHO’s Current Focus and Initiatives

The WHO is actively supporting countries to integrate eye health services at the primary care level as part of universal health coverage. This includes providing technical support to countries like Ethiopia, Ghana, Niger, Nigeria, Somalia, and Zambia through national situational analyses, strategic plans, and monitoring frameworks. The SPECS 2030 initiative aims to increase the number of people with access to appropriate spectacles, targeting an effective coverage of refractive error (eREC) of 40% by 2030. Liberia and Mozambique have begun implementing this initiative. Furthermore, the WHO has launched a free self-assessment tool called WHOeyes to promote healthy habits and raise eye care awareness. This tool is available in multiple languages and helps check visual acuity while providing educational messaging.

Economic and Social Impact

Good vision significantly impacts overall well-being, academic achievements, and economic growth. Therefore, addressing eye health challenges is crucial for broader societal benefits.

In summary, while there has been progress in reducing certain causes of blindness in Africa, significant challenges persist, including financial and human resource constraints, low community awareness, and emerging eye health issues related to noncommunicable diseases. The WHO is committed to addressing these challenges through various initiatives and support programs aimed at improving eye health in the African region.

Reference url

Recent Posts

Rare Medications Coverage in the Netherlands: Price Reductions Required

By Staff Writer

August 15, 2025

Zorginstituut Nederland has announced that two rare disease medications, exagamglogene autotemcel (Casgevy®) and omaveloxolon (Skyclarys®), will only be covered by Dutch basic health insurance if their prices drop significantly. For omaveloxolon, treating Friedreich's ataxia, an 84% price cut is ...
Strengthening the U.S. Pharmaceutical Supply Chain: Establishing a Strategic API Reserve
The recent White House executive action introduces the establishment of a Strategic Active Pharmaceutical Ingredients (API) Reserve. This aims to bolster the resilience of the U.S. Pharmaceutical Supply Chain. The directive mandates federal support for domestic production of critical APIs. It inc...
Most Expensive Drugs 2025: Trends and Implications in US Pharma Pricing

By João L. Carapinha

August 13, 2025

What are the most expensive drugs 2025, and how do they shape patient access, healthcare spending, and industry innovation in the US? As 2026 approaches, the most expensive drugs 2025 are led by advanced gene therapies and rare disease biologics, with several treatments carrying annual price tags...